Go Pro
NASDAQ:YI

111 Q2 2025 Earnings Report

111 logo
$3.79 -0.31 (-7.66%)
As of 12:42 PM Eastern
This is a fair market value price provided by Massive. Learn more.

111 EPS Results

Actual EPS
-$0.40
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

111 Revenue Results

Actual Revenue
$447.51 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

111 Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Tuesday, September 16, 2025
Conference Call Time
6:00PM ET

Upcoming Earnings

111's Q2 2026 earnings is estimated for Thursday, August 20, 2026, based on past reporting schedules

Earnings Documents

111 Earnings Headlines

111, Inc. Sponsored ADR
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Trump has issued emergency support to accelerate the rollout, and it's already live in multiple states. The Financial Times reports Sam Altman is personally calling people to build this for OpenAI. A few little-known companies control the entire supply chain - meaning anyone who wants access must go through them. Their stocks are available to buy right now.tc pixel
See More 111 Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like 111? Sign up for Earnings360's daily newsletter to receive timely earnings updates on 111 and other key companies, straight to your email.

About 111

111 (NASDAQ:YI), Inc. (NASDAQ: YI) is a leading online pharmacy e-commerce platform in China, operating under the brand 111.com. The company provides consumers with a comprehensive selection of pharmaceutical and healthcare products through its proprietary digital channels, including a website and mobile applications. By integrating online ordering, prescription management, and direct-to-consumer delivery, 111, Inc. aims to streamline the purchase of medicines and health-related goods for customers nationwide.

111, Inc.’s product portfolio encompasses prescription and over-the-counter drugs, nutritional supplements, vitamins, maternal and child care items, personal care products, and beauty goods. The platform offers specialized services for prescription fulfillment, enabling users to upload medical prescriptions securely and receive licensed medications through certified pharmacy partners. In addition to its core pharmaceutical offerings, the company features a curated selection of imported wellness and beauty brands sourced from markets such as the United States, Europe, and Japan.

With a focus on cross-border e-commerce, 111, Inc. partners with domestic manufacturers and international suppliers to ensure product authenticity and quality control. The company operates strategically located warehouses to facilitate efficient order processing and delivery, leveraging both direct shipping from overseas distributors and local inventory hubs. Its digital infrastructure supports real-time inventory tracking, customer support, and data-driven recommendations to enhance the consumer experience.

Founded in 2010 and headquartered in Shanghai, 111, Inc. has grown alongside China’s expanding digital healthcare market. Its management team brings together expertise in online retail, supply chain logistics, and regulatory compliance to navigate the complexities of pharmaceutical distribution. Through ongoing platform enhancements and strategic partnerships, 111, Inc. continues to expand its reach and service offerings in China’s rapidly evolving healthcare e-commerce landscape.

View 111 Profile